Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Completes Ibis Acquisition

NEW YORK (GenomeWeb News) – Abbott has completed its acquisition of molecular diagnostics firm Ibis Biosciences from Isis Pharmaceuticals for total consideration of $215 million plus earn-out payments.
 
Abbott said last month that it had exercised its option to acquire the remaining 81.4 percent stake of Ibis Biosciences that it didn’t already own for $175 million.
 
Earlier in 2008, Abbott acquired an 18.6 percent stake in Ibis, which is the molecular diagnostics subsidiary of Isis Pharmaceuticals, in two tranches for $40 million. At that time, it took an exclusive option to acquire the remaining interest in Ibis by June 30, 2009, for $175 million to $195 million, plus an earn-out tied to sales of instruments and assay kits.
 
Ibis sells the Ibis T5000 Biosensor System, which is used for rapid identification and characterization of infectious agents. It is currently used for research purposes, but Abbott intends to seek US Food and Drug Administration clearance of the system for clinical diagnostics applications.
 
“This acquisition will enable Abbott to offer an innovative approach to the detection and characterization of a broad array of pathogens for the management of infectious diseases,” Stafford O’Kelly, vice president of molecular diagnostics for Abbott, said in a statement today.
 

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.